Carlsmed Reports Strong Q1 Revenue Growth, Improved Margins, and Positive CMS Reimbursement Developments

summarizeSummary

Carlsmed reported strong Q1 2026 revenue growth and improved gross margins, driven by increased adoption of its spine surgery platform. Key product and regulatory milestones, including a positive CMS reimbursement proposal, underpin a positive outlook despite increased operating losses.

check_boxKey Events

• Strong Revenue Growth

  Revenue for the first quarter of 2026 increased by 58.2% year-over-year to $16.116 million, reflecting continued commercial adoption of the aprevo Technology Platform.

• Improved Gross Margin

  Gross margin improved to 77.1% in Q1 2026, up from 74.9% in Q1 2025, primarily due to cost improvements per unit from contract manufacturers.

• Increased Net Loss and Cash Burn

  Net loss for Q1 2026 increased to $(8.696) million from $(5.729) million in Q1 2025, and net cash used in operating activities rose to $(13.007) million, as the company continues to invest in product development and commercial expansion.

• Positive CMS Reimbursement Developments

  CMS released a proposal on April 10, 2026, for new MS-DRG coding that would reassign aprevo lumbar procedures to new codes, potentially providing additional reimbursement for hospital customers. NTAP for aprevo cervical inpatient procedures is effective October 1, 2025.

auto_awesomeAnalysis

Carlsmed, Inc. reported robust first-quarter 2026 results, demonstrating significant commercial traction with a 58.2% year-over-year revenue increase and an improved gross margin. The company continues to expand its product portfolio with successful initial procedures for new cervical plating and bi-lateral lumbar solutions, signaling future growth opportunities. Critically, the recent CMS proposal for new MS-DRG codes for aprevo lumbar procedures, if finalized, represents a strong validation of the platform's value and could drive enhanced market adoption through additional reimbursement clarity. While net losses and cash burn increased due to continued investment in R&D and commercial expansion, the company maintains a solid liquidity position with over $97 million in cash and investments, projecting a runway of at least 12 months. The cashless exercise of warrants during the quarter also removes a potential overhang.